Vasopressin response and shunting modulation in cirrhotic rats by chronic nitric oxide inhibition

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 7 PT2, 2008, Pages

  Huang, Hui Chun ^a,c   Wang, Sun Sang ^b,c   Lee, Fa Yauh ^a,c   Chang, Ching Chih ^b,c   Chang, Full Young ^a,c   Lin, Han Chieh ^a,c   Hou, Ming Chih ^a,c   Lee, Shou Dong ^a,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b TAIPEI MUNICIPAL GAN DAU HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Bile duct ligation; Cirrhosis; Nitric oxide; Portal systemic collaterals; Vasopressin

Indexed keywords

ARGIPRESSIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; TAP WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BILE DUCT LIGATION; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL REACTIVITY; COLLATERAL CIRCULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FLOW RATE; HEART RATE; LIVER CIRRHOSIS; MALE; NONHUMAN; PERFUSION PRESSURE; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; VASCULAR RESISTANCE;

EID: 47649111142     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.05122.x     Document Type: Article

References (32)

1. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am. J. Physiol. 1983 244 : G52 7.
2. Schrier RW, Caramelo C. Hemodynamic and hormonal alternations in hepatic cirrhosis. In : Epstein M, ed. The Kidney in Liver Disease. Baltimore : Williams & Wilkins, 1988 265 85.
3. Pizcueta P, Pique JM, Fernandez M et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992 103 : 1909 15.
4. Pizcueta MP, Pique JM, Bosch J, Whittle BJ, Moncada S. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br. J. Pharmacol. 1992 105 : 184 90.
5. Lee FY, Colombato LA, Albillos A, Groszmann RJ. Administration of N omega-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 1993 105 : 1464 70.
6. García-Pagán JC, Fernández M, Bernadich C et al. Effects of continued NO inhibition on portal hypertensive syndrome after portal vein stenosis in rat. Am. J. Physiol. 1994 267 : G984 90.
7. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985 5 : 419 24.
8. D'Amico G, Pagliare L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995 22 : 322 54.
9. Valla D, Geoffroy P, Girod C, Lebrec D. Circulatory actions of vasopressin in anesthetized rats with portal hypertension subjected to hemorrhage. J. Hepatol. 1986 2 : 328 39.
10. Lee FY, Albillos A, Colombato LA, Groszmann RJ. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology 1992 16 : 1043 8.
11. Sieber CC, Groszmann RJ. In vitro hyporeactivity to methoxamine in portal hypertensive rats: reversal by nitric oxide inhibition. Am. J. Physiol. 1992 262 : G996 1001.
12. Thiemermann C, Szabó C, Mitchel JA, Vane JR. Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. Proc. Natl. Acad. Sci. USA 1993 90 : 267 71.
13. Kravetz D, Cummings SA, Groszmann RJ. Hyposensitivity to vasopressin in a hemorrhage-transfused rat model of portal hypertension. Gastroenterology 1987 93 : 170 5.
14. Valla D, Girod C, Lee SS, Braillon A, Lebrec D. Lack of vasopressin action on splanchnic hemodynamics during bleeding: a study in conscious, portal hypertensive rats. Hepatology 1988 8 : 10 15.
15. Tsai YT, Lee FY, Lin HC et al. Hyposensitivity to vasopressin in patients with hepatitis B-related cirrhosis during acute variceal bleeding. Hepatology 1990 13 : 407 12.
16. Chu CJ, Lee FY, Wang SS et al. Aminoguanidine ameliorates splanchnic hyposensitivity to glypressin in a haemorrhage-transfused rat model of portal hypertension. Clin. Sci. 1998 95 : 629 36.
17. Huang HC, Chu CJ, Lee FY et al. Chronic inhibition of nitric oxide ameliorates splanchnic hyposensitivity to glypressin in a hemorrhage-transfused rat model of portal hypertension. Scand. J. Gastroenterol. 2000 35 : 1308 13.
18. Huang HC, Wang SS, Chan CC et al. Chronic inhibition of nitric oxide increases the collateral vascular responsiveness to vasopressin in portal hypertensive rats. J. Hepatol. 2004 40 : 234 8.
19. Chojkier M, Groszmann RJ. Measurement of portal-systemic shunting in the rat by using gamma-labeled microspheres. Am. J. Physiol. 1981 240 : G371 5.
20. Fernandez M, Pizcueta P, Garcia-Pagan JC et al. Effects of ritanserin, a selective and specific S2-serotoninergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation. Hepatology 1993 18 : 389 93.
21. Mosca P, Lee FY, Kaumann AJ, Groszmann RJ. Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of endothelium. Am. J. Physiol. 1992 263 : G544 50.
22. Chan CC, Lee FY, Wang SS et al. Effects of vasopressin on portal-systemic collaterals of portal hypertensive rats: role of nitric oxide and prostaglandin. Hepatology 1999 30 : 630 5.
23. Chan CC, Wang SS, Lee FY et al. Endotheline-1 induced vasoconstriction on portal-systemic collaterals of portal hypertensive rats. Hepatology 2001 33 : 816 20.
24. Hamilton RL, Berry MN, Williams MC, Severinghaus EM. A simple and inexpensive membrane 'lung' for small organ perfusions. J. Lipid Res. 1974 15 : 182 6.
25. Bosch J, Mastai R, Kravetz D, Bruix J, Rigau J, Rodés J. Measurement of azygous venous blood flow in the evaluation of portal hypertension in patients with cirrhosis: clinical and haemodynamic correlations in 100 patients. J. Hepatol. 1985 1 : 125 39.
26. Chan CC, Wang SS, Lee FY et al. Effects of vasopressin on portal-systemic collaterals of cirrhotic rats. Scand. J. Gastroenterol. 2005 40 : 83 9.
27. Tanoue K, Ohta M, Tarnawski AS, Wahlstrom KJ, Sugimachi K, Sarfeh IJ. Portal hypertension activates the nitric oxide synthase genes in the esophageal mucosa of rats. Gastroenterology 1996 110 : 549 57.
28. Graebe M, Brond L, Christensen S, Nielsen S, Olsen NV, Jonassen TE. Chronic nitric oxide synthase inhibition exacerbates renal dysfunction in cirrhotic rats. Am. J. Physiol. 2004 286 : F288 97.
29. Sarin SK, Groszmann RJ, Mosca PG et al. Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension. J. Clin. Invest. 1991 87 : 1032 6.
30. Sumanovski LT, Battegay E, Stumm M, Van Der Kooij M, Sieber CC. Increased angiogenesis in portal hypertensive rats: role of nitric oxide. Hepatology 1999 29 : 1044 9.
31. Sieber CC, Sumanovski LT, Stumm M, van der Kooij M, Battegay E. In vivo angiogenesis in normal and portal hypertensive rats: role of basic fibroblast growth factor and nitric oxide. J. Hepatol. 2001 34 : 644 50.
32. Polio J, Groszmann RJ, Reuben A, Sterzel RB, Better OS. Portal hypertension ameliorates arterial hypertension in spontaneously hypertensive rats. J. Hepatol. 1989 8 : 294 301.